8-K: Scholar Rock Advances SMA Drug, Initiates FSHD Trial

Scholar Rock reported Q2 2026 results, highlighting progress on its apitegromab BLA with a potential FDA approval by September 30, 2026, and initiating a Phase 2 trial for FSHD.

Summary

• Scholar Rock reported its financial and operating results for the second quarter ended June 30, 2026.
• The company's apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) is on track for a potential FDA approval by the September 30, 2026 PDUFA date.
• Two independent fill-finish facilities are progressing towards FDA approval, ensuring ample commercial supply.
• The company initiated a Phase 2 FORGE study evaluating apitegromab in patients with facioscapulohumeral muscular dystrophy (FSHD).
• Scholar Rock reported a net loss of $109.9 million for Q2 2026, compared to $110.0 million in Q2 2025.
• Net loss per common share was $0.84 for Q2 2026, compared to $0.98 in Q2 2025.
• The company had no revenue for the quarters ended June 30, 2026, and 2025.
• Research and development expenses were $58.2 million in Q2 2026, down from $62.4 million in Q2 2025.
• General and administrative expenses were $50.7 million in Q2 2026, up from $49.7 million in Q2 2025.
• As of June 30, 2026, the company held $492.1 million in cash, cash equivalents, and marketable securities, including $62.8 million from its at-the-market program.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by significant progress in regulatory submissions and clinical trial initiations, balanced by continued operational losses.

Positives

• Apitegromab BLA for SMA is on track for potential FDA approval by September 30, 2026 (PDUFA date).
• Two independent fill-finish facilities are advancing, ensuring commercial supply readiness.
• Initiated Phase 2 FORGE study for apitegromab in FSHD patients.
• Cash, cash equivalents, and marketable securities increased to $492.1 million as of June 30, 2026.
• Net cash proceeds of $62.8 million were raised from the at-the-market (ATM) program during the quarter.
• Net loss for Q2 2026 was slightly down compared to Q2 2025 ($109.9 million vs. $110.0 million).
• Net loss per share improved in Q2 2026 compared to Q2 2025 ($0.84 vs. $0.98).

Negatives

• The company reported no revenue for the second quarter of 2026.
• Continued significant net loss of $109.9 million for the quarter.
• General and administrative expenses increased to $50.7 million from $49.7 million in the prior year quarter.
• FDA inspection classification of Catalent Indiana is pending.

Risks

• The FDA inspection classification of Catalent Indiana following a general site inspection is pending.
• Whether preclinical and clinical data will be sufficient to support regulatory approval or further development.
• Preclinical and clinical data may not be predictive of, or may be inconsistent with, data generated from future or ongoing clinical trials.
• Whether the FDA will accept remediations to the Catalent Indiana fill-finish facility in response to FDA observations.
• Whether the updated BLA, including a second fill-finish facility, will be sufficient to support regulatory approval.
• Scholar Rock's ability to manage expenses or provide the financial support, resources, and expertise necessary to identify and develop product candidates on the expected timeline.
• Decisions made by regulatory authorities.
• Competition from third parties developing products for similar uses.

Future Outlook

The company anticipates potential FDA approval for apitegromab by September 30, 2026, with readiness for a U.S. launch immediately thereafter. Engagement with the EMA for the Marketing Authorisation Application is ongoing, with updated timelines expected upon alignment. Topline data from the Phase 1 study of SRK-439 in healthy volunteers is anticipated in late 2026.

Management Comments

• "We are on the threshold of securing the worlds first ever regulatory approval of a myostatin inhibitor, which will also be the first ever muscle-targeted treatment for children and adults living with SMA," said David L. Hallal, Board Chair and Chief Executive Officer of Scholar Rock.
• "Backed by a strong balance sheet, our Scholar Rock team is ready to usher in the next phase of innovation for the SMA community in the U.S. immediately upon apitegromab approval."

Industry Context

StockSavvy.ai notes that Scholar Rock's progress in advancing apitegromab towards potential approval in SMA places it at the forefront of rare neuromuscular disease treatments. The initiation of the FORGE trial for FSHD demonstrates a strategic expansion of its pipeline leveraging its core myostatin platform, aligning with industry trends towards targeted therapies for debilitating conditions.

Stakeholder Impact

• Shareholders: Potential for significant value creation if apitegromab receives FDA approval, offset by continued operational losses and R&D expenses.
• Patients with SMA: Potential for a new, first-in-class muscle-targeted treatment.
• Patients with FSHD: Potential for a new treatment option through the ongoing Phase 2 FORGE trial.
• Employees: Continued focus on R&D and regulatory milestones, with potential for growth if commercialization is successful.

Next Steps

• Await FDA inspection classification of Catalent Indiana.
• Await FDA decision on apitegromab BLA by September 30, 2026.
• Prepare for U.S. commercial launch of apitegromab upon FDA approval.
• Align with EMA on next steps for apitegromab Marketing Authorisation Application (MAA).
• Provide updated guidance on EMA timelines upon alignment.
• Continue enrollment and dosing in Phase 2 OPAL trial for SMA.
• Engage with FDA and EMA on development path for subcutaneous apitegromab.
• Anticipate topline data from Phase 1 study of SRK-439 in late 2026.

Key Dates

Recommendation

The company is making significant progress towards a potential regulatory approval for its lead asset, apitegromab, which is a strong positive. However, the lack of current revenue, continued substantial net losses, and the inherent risks in drug development and regulatory approvals warrant a cautious 'hold' stance until approval is secured and commercialization begins.

Keywords

Apitegromab, Spinal Muscular Atrophy, Facioscapulohumeral Muscular Dystrophy, Myostatin Inhibitor, Biologics License Application, Clinical Trial, Biopharmaceutical, Neuromuscular Disease